secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001171843-23-004029
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV
--------------------------------------------------------------------------------

- First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.
- Arm evaluates low-dose nivolumab plus VTP-300 boosters after AB-729 and NA therapy to reduce HBsAg in chronic HBV.
- Preliminary data from this arm expected in 2024; original arm data expected H2 2023.
- Enrollment complete in original arm; approximately 20 patients to be enrolled in new open-label arm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/0001171843-23-004029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/f8k_062123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer